Alpha Tau Medical Ltd. filings document the company's foreign-issuer current reports for Alpha DaRT clinical and regulatory updates. Recent Form 6-K reports furnish press releases and presentations covering studies in recurrent glioblastoma, recurrent cutaneous squamous cell carcinoma, pancreatic cancer, and head and neck cancer.
The filings describe trial enrollment, interim clinical data, safety observations, FDA device-related matters, conference presentations and company presentations furnished as exhibits. They also identify the company's Form 20-F reporting status and the treatment of furnished information under the Securities Exchange Act.
Alpha Tau Medical Ltd. submitted a Form 6-K noting that it issued a press release titled “Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference.” The press release, dated December 18, 2025, is included as an exhibit to the report. The company clarifies that the information in this Form 6-K, including the exhibit, is being furnished rather than filed, which limits its potential liability under U.S. securities laws and controls how it may be incorporated into other regulatory documents.
Alpha Tau Medical Ltd. filed a Form 6-K to furnish a press release titled “Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update,” dated November 20, 2025. The report incorporates this press release by reference into the company’s existing Form F-3 and Form S-8 registration statements.
Alpha Tau Medical Ltd. (DRTS) furnished a Form 6-K noting it issued a press release titled “Alpha Tau Announces Receipt of Radioactive Material License at New Hampshire Manufacturing Facility.”
The submission states the information is being furnished, not deemed filed, and includes the press release as Exhibit 99.1 dated October 21, 2025.
Form 144 notice for Alpha Tau Medical Ltd. (DRTS) reports a proposed sale of 16,000 ordinary shares through Oppenheimer & Co. with an aggregate market value of $72,160. The shares represent a small fraction of the reported 70,380,570 outstanding shares (approximately 0.023%). The securities were acquired on 02/21/2017 under an employee stock options plan and the proposed approximate sale date is 10/01/2025 with payment described as cash upon exercise. The filing indicates no securities sold by the same person in the past three months. Several standard signature and date fields in the remarks section appear in the form but no specific signature, notice date, or plan-adoption date text values are provided in the content supplied.